Introduction
Cutaneous squamous cell carcinoma (cSCC) is a common skin cancer with an incidence rate of 12-29/100,000/ year in Europe and 700/100,000/year in Australia [1] [2] [3] [4] [5] [6] [7] . Populations with fair skin that experience high cumulative UV exposure are at highest risk for cSCC development, sun-exposed areas being majorly affected [8] [9] [10] .
The treatment of choice for invasive cSCC is surgery, particularly Mohs micrographic surgery [11] [12] [13] [14] [15] [16] producing the lowest recurrence rates. In elderly patients with problematic co-morbidities and critical tumor localizations, radiotherapy (RTx) can be an alternative option [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] , but reports of superficial RTx and data on longterm outcome are limited [17, [19] [20] 22] .
In the following, relapse rates of cSCCs after superficial RTx are reported from a retrospective study. Data are correlated with the tumors' histological differentiation and anatomical distribution.
the patients (mostly due to the patient's co-morbidities combined with tumor size and localization). The decision to treat with RTx instead of surgery was individually taken by the physician together with the patient. Overall, patients were offered treatment with superficial RTx if they were of high age and presented a lesion of large size or localized at difficult sites. Patients who were lost to follow-up were sent a new appointment for consultation. Patients treated after 2004 were not included in the study in order to keep a standard as the equipment changed afterwards.
The diagnoses were histologically confirmed by H&E staining prior to treatment. Lesion size was measured by multiplying the two largest diameters that were perpendicular to each other. Superficial RTx was performed using Dermax 4000, a berylliumwindowed soft X-ray machine (R. Liechti AG, Kriegstetten, Switzerland) using 10, 20, 30, 40 or 50 kV. A field margin of 1 cm to the clinical tumor edges was applied. The administered electric potential ranged from 30 to 60 kV. Depending on the thickness of the interposed aluminum filter (0.5-2.0 cm), the electric current (20 mA), the focus-skin distance (3-20 cm) and the resulting half value layer (4-15 mm) varied.
Relapse rates according to the patient's age, tumor localization and histological differentiation grade (according to standard criteria [27] ) were analyzed retrospectively.
Statistical Analysis
GraphPad Prism (version 5.00 for Windows, GraphPad Software, San Diego, Calif., USA) was used for statistical analyses. Overall and recurrence-free survival, depending on the patient's age, tumor localization and differentiation grade, was analyzed using Kaplan-Meier and Cox regression. A p value ! 0.05 was considered to be significant; a 95% confidence interval (CI) was computed. 95% CI 36.1-38.4) and a mean electric current of 11.0 mA (SD 3.2, 95% CI 10.5-11.5) ( table 4 ) . Follow-up visits were attended for more than 1 year in 136 patients (75.6%); 69 patients attended for more than 5 years (38.3%), and 23 (12.8%) for more than 10 years (visits every 6 months). The mean follow-up period was 4.9 years (SD 4.7; 95% CI 4.2-5.6).
Results

patients (
Relapses and Overall Relapse-Free Survival
Of the 180 lesions, 24 relapses (13%) were registered with a mean delay of 2.7 years (SD 2.98, 95% CI 1.40-3.92) after start of superficial RTx. One of these lesions revealed lymph node infiltration 1.7 years after treatment. All relapsed cSCCs were originally primary tumors before treated with superficial RTx. Except for 1 case which was located on the lower limbs, all relapsed cSCCs originated from the head and neck area, all deriving from primary tumors. Unfortunately, information about the accurate localization of the relapses within the radiated area (center versus edge) is not retraceable retrospectively. Apart from two cases -one patient with colon cancer, one with chronic lymphatic leukemia -there is no evidence for immunodeficiency in the patients who experienced a relapse ( table 3 ) . The risk for relapses after RTx increased significantly with age (p = 0.012) and correlated significantly with tumor size (p 1 0.0001, Cox regression). The overall relapse-free survival 1, 2, 5 and 10 years after superficial RTx was 95.8, 91.5, 86.2 and 80.4%, respectively ( fig. 1 ).
Relapse-Free Survival and Histological Differentiation Grade
Histological differentiation grade is known in 81.7% (n = 147). Tumor size and histological differentiation correlated significantly (p ! 0.0011, two-tailed paired t test). Of these lesions, well differentiated ones relapsed in 11.2% (11/98), moderately differentiated ones in 15.2% (5/33) and poorly differentiated ones in 25% (4/16). The number of cases is too small to reach a significant level, however there is a trend for a better outcome for well differentiated cSCCs (p = 0.1). Relapse-free survival after 1, 2, 5 and 10 years was 97.4, 94.8, 89.3 and 82.1% in well differentiated tumors, 96.3, 88.9, 80.7 and 80.7% in moderately differentiated tumors, and 92.9, 85.7, 77.9 and 39.0% in poorly differentiated tumors ( table 5 ; fig. 1 , 2 ) .
Relapse-Free Survival and Tumor Localization
The number of tumor sites other than the head and neck was too small to perform further differentiation. Concerning the head and neck area, the distinguished sites were classified as areas around the ears, eyes, nose, lips, cheeks, scalp, forehead and neck. cSCCs around/at the ears and scalp presented significantly higher relapse rates (p = 0.025) compared to other sites: five-year relapse-free survival was 69.2% for tumors on the scalp, 72.2% for tumors around the ears, while lesions around the eyes and cheeks revealed 100 and 90.9% five-year relapse-free survival. Tumors located on the remaining body parts other than the head and neck area were mostly located on the extremities and showed relapse-free survival of 94.7% at 5 years ( tables 1 , 2 , 6 ). Figure 3 illustrates 3 clinical examples before treatment and clinical outcome after treatment. Figure 4 shows the histology of an SCC (Bowen carcinoma) before and after treatment.
Discussion
For the treatment of superficial cSCCs, different treatment modalities have been approved [11, 16, 25] , while for invasive cSCCs nowadays standard treatment is sur- [29] . Besides, radical excision of large cSCCs or cSCCs localized at difficult sites may lead to functional and cosmetic complications with the risk of mutilations and dysfunctions. Also for patients of advanced age who present multiple co-morbidities, wide excision -even if tumescent anesthesia is used -may be detrimental, and often hospitalization is required in this patient group [13] . Other skin tumors are effectively treated with superficial RTx -basal cell carcinoma with a recurrence rate of 16% after 5 years, and lentigo maligna and lentigo maligna melanoma with 7% after 8 years as studies showed in the past [30, 31] . For specific cases, RTx can be superior to surgery concerning cosmesis and functional results [22, 32] even in view of possible late adverse events [33, 34] . Taking these advantages into account, we retrospectively evaluated our data on RTx-treated cSCCs over a long time period. Further studies registered relapse 
Figures are mean 8 SD unless indicated otherwise. rates of 7% 6 years after superficial RTx [35] and control rates of up to 80% in another clinical trial including 142 cSCCs (data are mixed with results of electron beam therapy) [22] . Another study including 111 patients with SCC registered a 5-year cure rate of 92.7% [36] . We found relapse-free survival in 95.8, 91.5 and 86.2% of patients 1, 2 and 5 years after RTx in large cSCCs with a mean diameter of 3.5 cm 2 . These data are in concordance with most previous studies, although we evaluated lesions at high risk of recurrences regarding the averaged lesion size of 1 2 cm, which itself has a higher recurrence rate [37] . A mean tumor size of 3.5 cm 2 alone does not necessarily imply a situation which is not feasible for surgery, but tumor localization played an additional and important role in the decision to perform superficial RTx, as did the patient's co-morbidities and the patient's choice.
We further show that differentiation into histological differentiation grades is of great importance regarding the excellent outcomes of relapse-free survival of 94.8% in well differentiated but only 85.7% in poorly differentiated tumors at 2 years. These data confirm that RTx is not recommended for poorly differentiated cSCCs, although other treatment options show high recurrence rates in these cases as well [38] . However, it has to be stated that these data only provide a trend and are not reliable in this case as already mentioned above.
We found a correlation between clinical outcome and tumor localization of the head and neck region showing the best prognosis for cSCCs of the eyes (no recurrence in 10 patients at 5 years), nose (95.2% recurrence-free) and cheeks (90.9% recurrence-free) while lesions from the scalp and ears were recurrence-free only in 69.2 and 72.2%, respectively (data refer to 5-years relapse-free survival). The underlying reason for the disparities in outcome may be suggested in the anatomical structures with a possible local invasion of the bones or cartilaginous tissue in the latter sites. Unfortunately, data about possible invasion cannot be collected retrospectively, but we did not register any metastases besides one case of cSCC from the scalp who developed lymph node metastases.
For young patients who present good surgical applicability, total excision should remain the treatment of choice. The same applies to immunocompromised patients though the low number of patients does not allow any statistically correct conclusion in this group. Patients with xeroderma pigmentosum may also profit from adjuvant RTx as case reports show normal response to RTx. Their defects in the DNA repair mechanism are believed to be specifically induced by UV radiation but not by RTx [39] . A limitation of the study is the fact that information about the localization of the relapses -e.g. in-field versus at the irradiation margins -is lacking. As tumor thickness is not retraceable in the majority of cases, classification of the tumors according to the American Joint Committee on Cancer is not possible. Furthermore, patient selection was individually performed and there were no standardized inclusion criteria as this was a retrospective study. Therefore, biases in patient selection, patient referral (as this study was performed in a center) and classification are possible. Larger prospective clinical trials are required to confirm the achieved results.
Conclusion
Superficial RTx is a safe and efficient treatment option for cSCCs localized around the mouth, eyes and nose in patients for whom surgery is hardly feasible without risking considerable side effects. It is particularly favorable for elderly patients for whom surgery would be an increased health risk and if functional or cosmetic impairment is expected.
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